Differential binding to human FcγRIIa and FcγRIIb receptors by human IgG wildtype and mutant antibodies

被引:60
作者
Armour, KL
van de Winkel, JGJ
Williamson, LM
Clark, MR
机构
[1] Univ Cambridge, Dept Pathol, Div Immunol, Cambridge CB2 1QP, England
[2] Univ Cambridge, Dept Haematol, Div Transfus Med, Cambridge CB2 1QP, England
[3] Univ Utrecht, Med Ctr, Dept Immunol, Immunotherapy Lab, Utrecht, Netherlands
[4] Genmab AS, NL-3508 AD Utrecht, Netherlands
[5] Natl Blood Serv, Cambridge CB2 2PT, England
关键词
IgG effector function; Fc gamma RII; human IgG; inhibitory Fc receptor;
D O I
10.1016/j.molimm.2003.08.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We are investigating the interactions of recombinant human IgG antibodies with Fc receptors to enable selection of a constant region giving minimal depletion of antigen-bearing cells. Eight variant constant regions were made by substituting motifs between human IgG subclasses in the lower hinge region and/or a specially close loop of the CH2 domain. Mutations in the lower hinge region were shown to eliminate FcgammaRI binding and monocyte activation [Eur. J. Immunol. 29 (1999) 2613]. Here, we detail interactions with FcgammaRIIa of the 131R and 131H allotypes and FcgammaRIIb. Lower hinge mutations caused large reductions in binding whereas modification of residues 327, 330 and 331 had less dramatic effects. However, like the wildtype IgG subclass binding hierarchies, the effect of the mutations varied between different receptors. We identified IgG1 variants which react with the activating receptor, FcgammaRIIa, at least 10-fold less efficiently than wildtype IgG1 but whose binding to the inhibitory receptor, FcgammaRIIb, is only four-fold reduced. Manipulation of interactions with FcgammaRIIb separately from those with activating receptors provides potential for designing antibodies with novel and effective combinations of attributes. In addition, insight is gained into the evolution of functional differences in human IgG subclasses. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:585 / 593
页数:9
相关论文
共 34 条
  • [1] Armour KL, 1999, EUR J IMMUNOL, V29, P2613, DOI 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO
  • [2] 2-J
  • [3] Atherton A, 2000, EUR J IMMUNOL, V30, P2540, DOI 10.1002/1521-4141(200009)30:9<2540::AID-IMMU2540>3.0.CO
  • [4] 2-S
  • [5] THE GENERATION OF A HUMANIZED, NON-MITOGENIC CD3 MONOCLONAL-ANTIBODY WHICH RETAINS INVITRO IMMUNOSUPPRESSIVE PROPERTIES
    BOLT, S
    ROUTLEDGE, E
    LLOYD, I
    CHATENOUD, L
    POPE, H
    GORMAN, SD
    CLARK, M
    WALDMANN, H
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (02) : 403 - 411
  • [6] STRUCTURE AND EXPRESSION OF HUMAN-IGG FCRII(CD32) - FUNCTIONAL-HETEROGENEITY IS ENCODED BY THE ALTERNATIVELY SPLICED PRODUCTS OF MULTIPLE GENES
    BROOKS, DG
    QIU, WQ
    LUSTER, AD
    RAVETCH, JV
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (04) : 1369 - 1385
  • [7] Clark MR, 1997, CHEM IMMUNOL, V65, P88
  • [8] CLARK MR, 1989, J IMMUNOL, V143, P1731
  • [9] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
    Clynes, RA
    Towers, TL
    Presta, LG
    Ravetch, JV
    [J]. NATURE MEDICINE, 2000, 6 (04) : 443 - 446
  • [10] Inhibitory signaling by B cell FcγRIIb
    Coggeshall, KM
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1998, 10 (03) : 306 - 312